盐酸伊立替康致迟发性腹泻作用机制及防治的研究进展.pdfVIP

9 9 2012 9 September, 2012, Vol.9, No.9 中国药物警戒第 卷第 期 年 月 R994.11; R979.1 B 1672- 8629 2012 08- 0535- 04 中图分类号： 文献标识码： 文章编号： （ ） 盐酸伊立替康致迟发性腹泻作用机制及防治的研究进展 100700 张晓光 张侠（北京军区总医院肿瘤科，北京 ） 综述伊立替康致迟发性腹泻发生机制以及预防和治疗药物的研究进展。 检索PUBMED 和中国知 摘要：目的 方法 网2001- 2011 年国内外相关文献，对伊立替康致迟发性腹泻进行分析。 伊立替康体内代谢过程受多种代谢酶、 结果 基因、蛋白的影响，多种药物对迟发性腹泻有不用程度的治疗作用。 了解伊立替康致迟发性腹泻的机制，可进 结论 一步提高该药的临床有效性和安全性。 UGT1A1 伊立替康；腹泻；尿苷二磷酸葡萄糖醛酸转移酶（ ）；防治 关键词： Study on the Development of the Mechanism of Action, Prevention and Treatment for Irinotecan- induced Diarrhea ZHANG Xiao-guang ZHANG Xia (Department of Oncology, the Military General Hospital of Beijing PLA, Beijing 100700, China) Abstract: Objective To review the mechanism of irinotecan-induced type diarrhea and the prevention and therapy for it. Methods Analyze the irinotecan-induced diarrhea based on the relevance literature searched on the PUBMED and CNKI from 2001 to 2011. Results Metabolic processes of irinotecan is affected by a variety of metabolic en－ zymes, genes and proteins. Many drugs have different therapeutic effects for the delayed diarrhea. Conlusion Make an in-depth understanding of the mechanism of irinotecan-induced delayed diarrhea, which can further improve its safety and efficacy. Key words: irinotecan; diarrhea; UGT1A1; prevention and treatment CPT- 11 7- - 10- [4- 1- - 1- ② 伊立替康（ ， 乙基 （ 哌啶） 便的次数超过化疗前的正常大便次数； 出现软便、稀